ObsEva SA Logo

ObsEva SA

Developed novel therapeutics for women's reproductive health and pregnancy.

OBSN | SW

Overview

Corporate Details

ISIN(s):
CH1260041939
LEI:
549300PNZ0UEJVKN1618
Country:
Switzerland
Address:
CHEMIN DES AULX 12, 1228 PLAN-LES-OUATES
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ObsEva SA is a clinical-stage biopharmaceutical company that was focused on the development and commercialization of novel therapeutics for women's reproductive health and pregnancy. Founded in 2012, the company's research centered on treatments for serious conditions from conception to birth, such as preterm labor. In February 2024, the company announced it was winding down its operations. Note: The provided sources contain conflicting information, identifying the company's industry as biopharmaceutical, not financial data services, and including unrelated content from a sports streaming website.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ObsEva SA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ObsEva SA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ObsEva SA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-03-17 N/A Non-Executive member Buy None 2,058.00 CHF
2022-03-16 N/A Non-Executive member Buy None 27,010.00 CHF
2022-03-15 N/A Non-Executive member Buy None 23,642.00 CHF
2022-02-08 N/A Non-Executive member Buy None 64,161.00 CHF
2022-02-01 N/A Non-Executive member Buy None 70,716.00 CHF
2022-01-24 N/A Non-Executive member Buy None 69,748.00 CHF
2022-01-11 N/A Non-Executive member Buy None 183,535.00 CHF
2022-01-10 N/A Non-Executive member Buy None 177,643.00 CHF

Peer Companies

Iterum Therapeutics plc Logo
Develops novel oral & IV anti-infectives to combat multi-drug resistant pathogens.
United States of America
ITRM
IVF HARTMANN Holding AG Logo
Produces and distributes medical supplies, wound care, and hygiene items for global healthcare.
Switzerland
VBSN
Jade Biosciences, Inc. Logo
Clinical-stage biotech developing therapies for autoimmune and inflammatory diseases.
United States of America
JBIO
Jaguar Health, Inc. Logo
Develops plant-based, non-opioid GI therapies for humans and animals.
United States of America
JAGX
Janux Therapeutics, Inc. Logo
Developing tumor-activated immunotherapies to treat cancer while minimizing systemic toxicities.
United States of America
JANX
Japan Tissue Engineering Co., Ltd. Logo
Pioneers regenerative medicine with tissue products, CDMO services, and research models.
Japan
7774
Jasper Therapeutics, Inc. Logo
Develops mast cell-depleting antibody therapies for chronic diseases and stem cell transplants.
United States of America
JSPR
Jazz Pharmaceuticals plc Logo
Develops medicines for serious diseases in neuroscience and oncology.
United States of America
JAZZ
Develops therapies for rare genetic diseases, CNS disorders, and regenerative medicine.
Japan
4552
JEIL PHARMACEUTICAL CO.,LTD Logo
Global manufacturer of pharmaceutical APIs, antibiotics, and injection-based treatments.
South Korea
271980

Talk to a Data Expert

Have a question? We'll get back to you promptly.